Tags

Type your tag names separated by a space and hit enter

Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception.
Eur J Pharmacol. 1999 Aug 13; 378(3):237-48.EJ

Abstract

Intrathecal administration of anandamide, delta9-tetrahydrocannabinol (THC) and (-)-3-[2-hydroxy-4-(1,1-dimethyheptyl)ptyl)phenyl]-4-(3-hydr oxypropyl)-cicloexan-1-ol (CP55,940) induced spinal antinociception accompanied by differential kappa-opioid receptor involvement and dynorphin A peptide release. Antinociception using the tail-flick test was induced by the classical cannabinoid THC and was blocked totally by 17,17'-bis(cyclopropylmethyl)-6',6,7,7'-tetrahydro-4,5,4'5'-diepoxy++ +-6,6'-(imino)[7,7'-bimorphinan]-3,3',14,14'-tetrol (norbinaltorphimine) indicating a significant and critical kappa-opioid receptor component. The endogenous cannabinoid, anandamide and the non-classical bicyclic cannabinoid, CP55,940, induced non-nor-BNI-sensitive effects. The N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazo le-carboxamide (SR141716A)-mediated attenuation of spinal antinociception imparted by the various cannabinoids indicates cannabinoid CB1 receptor involvement. THC-induced an enhancement of immunoreactive dynorphin A release which coincided with the onset, but not duration antinociception. The release of dynorphin A was also attenuated by SR141716A suggesting it is cannabinoid CB1 receptor-mediated. These data indicate a critical role for dynorphin A release in the initiation of the antinociceptive effects of the cannabinoids at the spinal level.

Authors+Show Affiliations

Department of Pharmacology and Toxicology, Virginia Commonwealth University/Medical College of Virginia, Richmond 23298-0613, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

10493099

Citation

Mason, D J., et al. "Cannabinoid Modulation of Dynorphin A: Correlation to Cannabinoid-induced Antinociception." European Journal of Pharmacology, vol. 378, no. 3, 1999, pp. 237-48.
Mason DJ, Lowe J, Welch SP. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. Eur J Pharmacol. 1999;378(3):237-48.
Mason, D. J., Lowe, J., & Welch, S. P. (1999). Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. European Journal of Pharmacology, 378(3), 237-48.
Mason DJ, Lowe J, Welch SP. Cannabinoid Modulation of Dynorphin A: Correlation to Cannabinoid-induced Antinociception. Eur J Pharmacol. 1999 Aug 13;378(3):237-48. PubMed PMID: 10493099.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. AU - Mason,D J,Jr AU - Lowe,J, AU - Welch,S P, PY - 1999/9/24/pubmed PY - 2001/3/28/medline PY - 1999/9/24/entrez SP - 237 EP - 48 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 378 IS - 3 N2 - Intrathecal administration of anandamide, delta9-tetrahydrocannabinol (THC) and (-)-3-[2-hydroxy-4-(1,1-dimethyheptyl)ptyl)phenyl]-4-(3-hydr oxypropyl)-cicloexan-1-ol (CP55,940) induced spinal antinociception accompanied by differential kappa-opioid receptor involvement and dynorphin A peptide release. Antinociception using the tail-flick test was induced by the classical cannabinoid THC and was blocked totally by 17,17'-bis(cyclopropylmethyl)-6',6,7,7'-tetrahydro-4,5,4'5'-diepoxy++ +-6,6'-(imino)[7,7'-bimorphinan]-3,3',14,14'-tetrol (norbinaltorphimine) indicating a significant and critical kappa-opioid receptor component. The endogenous cannabinoid, anandamide and the non-classical bicyclic cannabinoid, CP55,940, induced non-nor-BNI-sensitive effects. The N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazo le-carboxamide (SR141716A)-mediated attenuation of spinal antinociception imparted by the various cannabinoids indicates cannabinoid CB1 receptor involvement. THC-induced an enhancement of immunoreactive dynorphin A release which coincided with the onset, but not duration antinociception. The release of dynorphin A was also attenuated by SR141716A suggesting it is cannabinoid CB1 receptor-mediated. These data indicate a critical role for dynorphin A release in the initiation of the antinociceptive effects of the cannabinoids at the spinal level. SN - 0014-2999 UR - https://www.unboundmedicine.com/medline/citation/10493099/Cannabinoid_modulation_of_dynorphin_A:_correlation_to_cannabinoid_induced_antinociception_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(99)00479-3 DB - PRIME DP - Unbound Medicine ER -